Moderna Inc. is in the headlines after facing a class action lawsuit. The investor claim is pushing the stock down, however the company has also received $176 million in funds from the U.S. Government to develop influenza mRNA-based vaccines. This major backing has boosted institutional investor interest in Moderna. Nasdaq:MRNA is now reportedly 67% owned by institutional investors.
Despite competition in the field where Pfizer/BioNTech's mRNA shot has failed against the influenza strain B, Moderna's continued progress in forthcoming COVID-19 vaccines, specifically those tailored for anticipated summer variants, has boosted its competitive position. The breakthrough mRNA drug could also potentially treat devastating childhood diseases. Moderna has teamed up with Coursera to launch a free course on mRNA technology, indicating a push for public understanding and acceptance of the new wave of vaccines. Following a better-than-expected Q1, Moderna is preparing for potential RSV vaccine launch in the fall. Moderna's mRNA vaccine for RSV has been approved by the FDA for use in older adults.
Despite regulatory advances and promising trial data, some setbacks including the halting of an mRNA vaccine plant project in Kenya and puzzling skin side effects for an HIV vaccine remain hurdles for Moderna. However, even with these challenges Moderna's stock has rose by 22% YTD, indicating positive investor sentiment.
Moderna MRNA News Analytics from Wed, 11 Oct 2023 07:00:00 GMT to Sun, 18 Aug 2024 23:12:00 GMT - Rating 8 - Innovation 10 - Information 10 - Rumor 3
